Answers are grounded in this paper and cite their sources.
Dear Editor, Topical agents are the first‐line therapy for psoriasis and the treatment of choice for mild‐to‐moderate chronic plaque psoriasis. Patients with severe psoriasis often use topical therapies at least for selected body areas.1,2 Corticosteroids and vitamin D analogues are effective, commonly used topical therapies for mild‐to‐moderate plaque psoriasis and are often used in combination due to their complementary pharmacodynamic activities.3 The availability of high‐quality generic topical drug products is constrained due to the limited methods accepted for bioequivalence evaluation of these products and the high cost and time required.4 A study was conducted to demonstrate that treatment with the generic ointment Calcipotriol–Betamethasone Sandoz (Lek Pharmaceuticals d.d.) is therapeutically equivalent to the originator product Daivobet® (Leo Pharma A/S, Ballerup, Denmark) and superior to vehicle in the treatment of chronic stable plaque psoriasis. The effects were determined by the percentage reduction in modified Psoriasis Area and Severity Index (mPASI). Both the generic and the reference product contained 50 μg of calcipotriol (as the monohydrate) and 0·5 mg of betamethasone (as the dipropionate) in 1 g of ointment. The vehicle was comprised of generic ointment formulation without active ingredients. A multicentre, randomized, double‐blind, active‐ and vehicle‐controlled study was conducted between January 2014 and August 2014 in Poland and Bulgaria (EudraCT: 2013‐002861‐20). The study was approved by the relevant independent ethics committees and health authorities. All patients gave written consent to participate before undergoing study‐related procedures. In total 444 male and female patients were enrolled. They were ≥ 18 years of age, with a clinical diagnosis of chronic stable plaque psoriasis (≥ 6 months before study start) amenable to topical treatment and involving the trunk and/or limbs but excluding the face, scalp, genitals and intertriginous areas. The body surface area affected by psoriasis was < 30% and the mPASI was between 5 and 15. Eligible patients were randomly assigned to study treatment in 4 : 4 : 1 ratio (see below). No more than 15 g of ointment was self‐administered by patients once daily in the evenings for 4 weeks. The primary end point was the mean percentage change from baseline in mPASI at the end of 4 weeks of treatment. As secondary end points, rates of > 50% reduction and > 75% reduction in mPASI were determined, affected body surface area (BSA) was estimated, the investigators assessed disease severity on a six‐point static Investigator's Psoriasis Global Assessment scale, and the patients assessed disease severity with a seven‐point dynamic Patient's Psoriasis Global Assessment scale. The comparison of the mean percentage change in mPASI from baseline was carried out using ancova adjusted by treatment and clinical centre as factors, and baseline PASI as a covariate. Overall 194 patients were treated with the test product, 201 with the reference product and 49 with the vehicle. One patient in the test group was excluded from the full analysis set (n = 443) due to unavailability of postbaseline PASI assessments. The treatment groups were comparable in baseline demographic and disease characteristics (reported as mean ± SD for the test, reference and vehicle groups): age 47·2 ± 14·2, 45·6 ± 14·2, 48·4 ± 13·0 years; body mass index 27·4 ± 4·5, 27·5 ± 5·1, 28·7 ± 4·8 kg m−2; duration of psoriasis 15·2 ± 11·7, 15·2 ± 12·6, 15·5 ± 12·2 years; mPASI 9·2 ± 2·9, 9·2 ± 3·0, 9·2 ± 2·8; BSA affected 12·7 ± 6·7, 12·9 ± 6·3, 12·3 ± 6·2%. The results showed that the test product was equivalent to the reference product, with a mean difference in the mean percentage change in mPASI after 4 weeks of treatment of 4·78% (Fig. 1a). The 95% confidence interval (0·78–8·78) was entirely within the prespecified equivalence range of ± 10 percentage points. The test group was superior to vehicle with the mean difference in percentage change in mPASI between the test product and the vehicle being 31·5% (95% confidence interval 25·1–37·9). The results for the primary end point obtained in this study are comparable with the results of previously conducted Daivobet pivotal studies.5,6,7,8 (a) Mean percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline over 4 weeks of treatment (full analysis set). The test product was already superior to its vehicle (P < 0·001) after 1 week of treatment and remained superior throughout the whole treatment period. (b) Proportion of patients with > 75% reduction in mPASI between baseline and the end of 4 weeks of treatment (defined as responders). A pairwise χ2‐test showed that the proportion of responders was significantly higher in the test product group compared with the reference (P = 0·01) or vehicle group (P < 0·001). (c) Change in the mean Investigator's Psoriasis Global Assessment (IPGA) score over 4 weeks of treatment. The test product showed superiority over vehicle in the mean percentage change in IPGA score at week 2 (P < 0·001) and week 4 (P < 0·001). At week 4, the mean percentage change in IPGA score was significantly greater for the test product than for the reference (P = 0·003). The test product was superior to vehicle in all secondary end points after 4 weeks of treatment (Fig. 1b, c), which demonstrates the assay sensitivity and confirms the validity of the primary end point. The test product was well tolerated and showed a safety profile comparable with that of the reference product, as the incidence and severity of lesional or perilesional adverse drug reactions were comparable and no significant changes in serum calcium and 24‐h urine cortisol levels could be observed. These results showed that even with better response rates in the secondary end points, treatment with Calcipotriol–Betamethasone Sandoz did not result in higher systemic exposure or cause any other safety concerns compared with the reference product. In conclusion, this study proved that the efficacy, safety and tolerability of generic Calcipotriol–Betamethasone Sandoz are equivalent to those of the reference product. We thank all of the participating investigators. Funding sources: the study was funded by Lek Pharmaceuticals d.d., a Sandoz company. The funder had a role in the study design, data collection, data analysis and manuscript preparation. Conflicts of interest: N.H. and D.G.‐P. are employees of Lek Pharmaceuticals d.d. R.K. is CEO of the contract research company CCDRD AG, which was contracted by Lek Pharmaceuticals d.d. to perform the clinical study reported in this paper. R.Y. participated as a coordinating investigator in the study. M.K.‐K. has no conflicts to declare.
No takes yet. Share an insight, caveat, or question.
Habjanič et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: